OpenAI’s model has significantly advanced the field of genetic engineering by offering innovative solutions for the evolution of molecules, demonstrating the potential to alter a third of the amino acids in proteins. This breakthrough was immediately applied by Retro, yielding real-world improvements in stem cell research, particularly in enhancing the original Yamanaka factors. The technology’s precise workings remain a mystery, akin to the initial enigma of AlphaGo’s strategies against human Go champions. Despite the promising scientific advancements, the collaboration between OpenAI and Retro raises questions regarding potential conflicts of interest, given OpenAI CEO’s investments in Retro through an “opaque investment empire.” OpenAI insists that no financial transactions occurred in this partnership and that Altman’s investments do not influence their decisions. Nonetheless, the association with OpenAI and Altman could significantly benefit Retro by elevating its profile and attracting more resources, although the company has not disclosed its current fundraising activities.
Read more at MIT Technology Review…
